These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 6958351)

  • 1. The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses.
    Green DM; Brecher ML; Blumenson LE; Grossi M; Freeman AI
    Cancer; 1982 Dec; 50(12):2722-7. PubMed ID: 6958351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
    J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.
    Sullivan MP; Chen T; Dyment PG; Hvizdala E; Steuber CP
    Blood; 1982 Oct; 60(4):948-58. PubMed ID: 6956376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of central nervous system prophylaxis with cranial radiation and intrathecal methotrexate versus intrathecal methotrexate alone in acute lymphoblastic leukemia.
    Muriel FS; Svarch E; Pavlovsky S; Eppinger-Helft M; Braier J; Vergara B; Garay G; Kvicala R; Divito JM; Failace R; Dibar E; Jimenez E
    Blood; 1983 Aug; 62(2):241-50. PubMed ID: 6575836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse.
    Brecher ML; Weinberg V; Boyett JM; Sinks LF; Jones B; Glicksman A; Holland JF; Freeman AI
    Cancer; 1986 Sep; 58(5):1024-8. PubMed ID: 3524797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
    Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
    Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.
    Gee TS; Haghbin M; Dowling MD; Cunningham I; Middleman MP; Clarkson BD
    Cancer; 1976 Mar; 37(3):1256-64. PubMed ID: 1063050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia (ALL).
    Freeman AI; Brecher ML; Wang JJ; Sinks LF
    Haematol Blood Transfus; 1979; 23():115-23. PubMed ID: 296106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia.
    Sackmann-Muriel F; Svarch E; Eppinger-Helft M; Braier JL; Pavlovsky S; Guman L; Vergara B; Ponzinibbio C; Failace R; Garay GE; Bugnard E; Ojeda FG; De Bellis R; de Sijvarger SR; Saslavsky J
    Cancer; 1978 Oct; 42(4):1730-40. PubMed ID: 101296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.
    Sallan SE; Hitchcock-Bryan S; Gelber R; Cassady JR; Frei E; Nathan DG
    Cancer Res; 1983 Nov; 43(11):5601-7. PubMed ID: 6352020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
    Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of acute lymphoblastic leukemia in children.
    Haghbin M
    Am J Hematol; 1976; 1(2):201-9. PubMed ID: 1069475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
    Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
    Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L.
    Dahl GV; Rivera GK; Look AT; Hustu HO; Kalwinsky DK; Abromowitch M; Mirro J; Ochs J; Murphy SB; Dodge RK
    J Clin Oncol; 1987 Jul; 5(7):1015-21. PubMed ID: 3474355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.